Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Demand normalisation post the second wave contributed to the steady growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
The company has tied up with OrbiMed as a financial partner for global reach
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The aim is to create new genomics solutions that could combat cancer and advance market access
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
